Upstream Bio (UPB) to Release Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) is projected to release its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Upstream Bio to post earnings of ($0.73) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 12:30 PM ET.

Upstream Bio Stock Down 4.4%

Shares of UPB stock opened at $7.36 on Wednesday. Upstream Bio has a 52-week low of $5.14 and a 52-week high of $33.68. The stock has a market cap of $397.73 million, a PE ratio of -3.91 and a beta of 2.96. The business has a 50-day simple moving average of $23.29 and a 200-day simple moving average of $22.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in UPB. Invesco Ltd. grew its stake in Upstream Bio by 6.4% in the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after acquiring an additional 985 shares during the period. JPMorgan Chase & Co. raised its position in Upstream Bio by 8.4% during the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock worth $181,000 after acquiring an additional 1,275 shares during the period. Legal & General Group Plc lifted its holdings in Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares in the last quarter. Empowered Funds LLC purchased a new position in Upstream Bio during the fourth quarter valued at $45,000. Finally, BNP Paribas Financial Markets grew its position in shares of Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on UPB shares. Mizuho raised Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Lifesci Capital began coverage on shares of Upstream Bio in a research note on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price for the company. Finally, Evercore initiated coverage on shares of Upstream Bio in a report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.